Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Thiol-disulfide exchange reactions are **dynamic covalent modifications** involving the reversible interchange between thiol (-SH) groups and disulfides (-S-S-) in proteins. These reactions play a crucial role in modulating the structure, function, localization, and stability of numerous extracellular and membrane-bound proteins. In the context of the immune system, such exchanges regulate key processes including immunoglobulin affinity maturation, T-cell receptor recognition, cytokine release, antigen presentation, and inflammatory signaling[1][6]. The process is often catalyzed by enzymes from the **thioredoxin superfamily**, notably **protein disulfide isomerases** (PDIs), which facilitate correct protein folding via formation/isomerization/reduction of disulfides[5]. During infection or inflammation, these modifications act as molecular switches that can rapidly alter protein activity—sometimes enabling pathogens like viruses to enter host cells through conformational changes triggered by reduction/oxidation events at critical cysteine residues on viral envelope glycoproteins. For example, inhibition of PDI-mediated thiol-disulfide interchange blocks HIV entry into lymphoid cells[2]. While essential for normal physiology—including adaptive immunity—these mechanisms also represent potential therapeutic intervention points but are not themselves discrete drug targets like receptors or enzymes. Instead they describe a class of biochemical reactions central to immune modulation. **Note:** "Immune system modulation via thiol-disulfide exchange reactions" describes a *mechanism* rather than a single molecular target; thus it does not fit standard definitions for canonical drug targets such as receptors or enzymes. It refers broadly to posttranslational regulatory chemistry affecting multiple molecules within immune pathways rather than one specific entity suitable for direct targeting by drugs.[1][6]
Inhibition of thiol-disulfide exchange can block viral entry by preventing conformational changes in viral envelope proteins required for cell fusion; this has been shown for HIV using PDI inhibitors such as bacitracin and anti-PDI antibodies[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Thiol-disulfide exchange reaction (in immune system modulation).